Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Shortages Mostly FDA’s Fault, House Oversight Committee Concludes

This article was originally published in The Pink Sheet Daily

Executive Summary

Report says aggressive enforcement in recent years has forced capacity offline, which led to shortages.

Advertisement

Related Content

Surge In Applications Triggers User Fee Inflation
Track & Trace – And Delay: Pharmacies Get Enforcement Discretion From FDA
FDA Policy Power Challenged In House Questions On Untitled Letters
FDA Policy Power Challenged In House Questions On Untitled Letters
FDA Policy Power Challenged In House Questions On Untitled Letters
User Fee Conference Cmte. Could Be Relatively Messy After Clean Floor Votes
GOP Drug Shortage Strategy Pushes FDA Reform, Reimbursement Over Notification
FDA’s Drug Shortage Prevention Tally: 96 Saves In Six Weeks
Medicare Reimbursement Rate Targeted As Culprit For Drug Shortages
To Prevent Drug Shortages, Don't Look To Inspections, FDA Says

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074287

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel